Phase 2 Study of Plamotamab Combined With Tafasitamab Plus Lenalidomide Versus Tafasitamab Plus Lenalidomide in R/R DLBCL
Condition(s):Diffuse Large-cell B-cell LymphomaLast Updated:May 9, 2023Terminated
Hide Studies Not Open or Pending
Condition(s):Diffuse Large-cell B-cell LymphomaLast Updated:May 9, 2023Terminated
Condition(s):Non-Hodgkin’s LymphomaLast Updated:May 18, 2020Terminated
Condition(s):Diffuse Large B-cell LymphomaLast Updated:January 31, 2023Terminated
Condition(s):Diffuse Large B-Cell LymphomaLast Updated:April 21, 2023Recruiting
Condition(s):NHL; NHL, Relapsed, AdultLast Updated:February 29, 2024Recruiting
Condition(s):Follicular Lymphoma; Lymphoma, Large B-Cell, DiffuseLast Updated:December 7, 2021Terminated
Condition(s):Relapsed or Refractory Diffuse Large B-cell LymphomaLast Updated:February 21, 2020Withdrawn
Condition(s):Diffuse Large B-cell LymphomaLast Updated:March 12, 2024Recruiting
Condition(s):B-cell Non-Hodgkin LymphomaLast Updated:March 18, 2024Active, not recruiting
Condition(s):Chronic Lymphocytic Leukemia; Non Hodgkin LymphomaLast Updated:December 19, 2023Active, not recruiting
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.